Celularity INC 10-Q quarterly reports

Celularity Inc. reported a significant increase in net losses and a substantial doubt about its ability to continue as a going concern, driven by declining product sales and ongoing operational expenditures.

Celularity Inc. reported significant losses and a going concern warning for Q2 2025, alongside Nasdaq delisting threats and multiple legal challenges.

Celularity Inc. reported a significant revenue decline and increased operating losses in Q1 2025, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice.

Celularity Inc. reports a significant increase in revenue for the third quarter of 2024, but continues to face substantial financial challenges and going concern uncertainties.

Celularity Inc. reported a significant increase in revenue for the second quarter of 2024, driven by its degenerative disease segment, but faces substantial financial challenges and uncertainties about its ability to continue as a going concern.

Celularity Inc. released its first quarter 2024 results, highlighting increased product sales but also significant operating losses and ongoing financial uncertainties.